NCT03568461
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03568461
Title Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA)
Acronym ELARA
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NOR | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS

Facility Status City State Zip Country Details
City of Hope National Medical Center Duarte California 91010 3000 United States Details
UCSF Medical Center San Francisco California 94143 United States Details
H Lee Moffitt Cancer Center and Research Institute Tampa Florida 33612 United States Details
Uni of Chi Medi Ctr Hema and Onco Chicago Illinois 60637 United States Details
Univ of Kansas Hosp and Med Ctr Kansas City Kansas 66160 United States Details
Michigan Med University of Michigan Ann Arbor Michigan 48109 5271 United States Details
Oregon Health Sciences University Portland Oregon 97239 United States Details
University of Pennsylvania Clinical Philadelphia Pennsylvania 19104 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Novartis Investigative Site Camperdown New South Wales 2050 Australia Details
Novartis Investigative Site Melbourne Victoria 3000 Australia Details
Novartis Investigative Site Herston QLD 4006 Australia Details
Novartis Investigative Site Linz 4020 Austria Details
Novartis Investigative Site Ghent 9000 Belgium Details
Novartis Investigative Site Paris 75475 France Details
Novartis Investigative Site Pierre-Bénite 69495 France Details
Novartis Investigative Site Munich Bavaria 81377 Germany Details
Novartis Investigative Site Cologne 50937 Germany Details
Novartis Investigative Site Ulm 89081 Germany Details
Novartis Investigative Site Bologna BO 40138 Italy Details
Novartis Investigative Site Milan MI 20132 Italy Details
Novartis Investigative Site Fukuoka Fukuoka 812-8582 Japan Details
Novartis Investigative Site Sapporo Hokkaido 060 8648 Japan Details
Novartis Investigative Site Sendai Miyagi 980 8574 Japan Details
Novartis Investigative Site Amsterdam North Holland 1081 HV Netherlands Details
Amsterdam UMC, locatie AMC Amsterdam 1105 AZ Netherlands Details
Novartis Investigative Site Oslo 0310 Norway Details
Novartis Investigative Site Seville Andalusia 41013 Spain Details
Novartis Investigative Site Madrid 28041 Spain Details
Novartis Investigative Site Birmingham B15 2TH United Kingdom Details
Novartis Investigative Site London SE5 9RS United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field